{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:56:23Z","timestamp":1790942183163,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Malignant ascites is a common, severe complication of advanced solid tumors, driven by multifactorial pathogenesis, including impaired lymphatic drainage, vascular endothelial growth factor-induced vascular hyperpermeability, pro-permeability inflammatory cytokines, and profound peritoneal immunosuppression. Clinically, it correlates with poor prognosis, reduced overall survival, and substantial quality-of-life deterioration. Current treatment remains predominantly palliative: repeated large-volume paracentesis offers transient symptom relief, fails to prevent reaccumulation, and carries procedural risks. Emerging evidence indicates malignant ascites is not merely passive fluid accumulation but an active, immunosuppressive niche shaped by bidirectional crosstalk among tumor cells, stromal components, diverse immune subsets (e.g., regulatory T cells, myeloid-derived suppressor cells, dysfunctional CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells), and soluble mediators. This narrative review summarizes recent advances in immunomodulatory treatment for malignant ascites, with an emphasis on strategies targeting the ascitic immune microenvironment. Intraperitoneal administration of immune checkpoint inhibitors has shown acceptable safety and preliminary activity in early-phase single-arm trials, although confirmatory data from larger controlled studies are lacking. In randomized trials, the T-cell engager catumaxomab prolonged puncture-free survival, while the bispecific antibody M701 has shown similar benefits in a phase II randomized controlled study; these findings support further investigation of localized T-cell redirection. Preclinical and early-phase clinical studies suggest that intraperitoneal oncolytic viruses can induce immunogenic tumor cell death and T-cell activation, with single-cell analyses indicating remodeling of the ascitic immune microenvironment. Future directions include integrating ascites immune phenotyping, patient-derived organoids for drug sensitivity testing, and machine learning-based decision support to guide personalized immunotherapy.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1893803","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:27:28Z","timestamp":1790940448000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging innovative immunotherapies in malignant ascites: current landscape, challenges and perspectives"],"prefix":"10.3389","volume":"16","author":[{"given":"Xian","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Oncology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbao","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241289517","article-title":"Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: A marker of peritoneal carcinomatosis burden","volume":"16","author":"Provenzano","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"31348251393930","DOI":"10.1177\/00031348251393930","article-title":"Incidence and outcomes of metastatic patterns of pancreatic ductal adenocarcinoma","volume":"92","author":"Jacobs","year":"2025","journal-title":"Am Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2021.04.010","article-title":"Optimal paracentesis volume for terminally ill cancer patients with ascites","volume":"62","author":"Ito","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07057-8","article-title":"Effect of paracentesis on the survival of patients with terminal cancer and ascites: a propensity score-weighted analysis of the East Asian Collaborative Cross-cultural Study to Elucidate the Dying Process","volume":"30","author":"Masuda","year":"2022","journal-title":"Supportive Care Cancer: Off J Multinational Assoc Supportive Care Cancer"},{"key":"B5","unstructured":"Pancreatic cancer associated ascites: Risk factors, outcomes, and management\n          \n          \n            \n              Wang\n              JD\n            \n            \n              Hendifar\n              AE\n            \n          \n          Journal of Clinical Oncology"},{"key":"B6","unstructured":"The prevalence and outcomes of ascites in patients hospitalized with pancreatic cancer: Insights from the Nationwide Inpatient Sample\n          \n          \n            \n              Tahboub\n              I\n            \n          \n          Journal of Clinical Oncology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101200","article-title":"Clinical risk factors for ascites in metastatic pancreatic cancer","volume":"8","author":"Berger","year":"2023","journal-title":"ESMO Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.11.008","article-title":"Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment","volume":"23","author":"Shi","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B9","article-title":"Autologous ex vivo expanded NK cells combined with PD-1 inhibitor improved ascitic fluid immune microenvironment of peritoneal metastatic pancreatic cancer: A case study","volume":"15","author":"Chen","year":"2023","journal-title":"Am J Transl Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14553-6","article-title":"Characterizing the immune environment in peritoneal carcinomatosis: Insights for novel immunotherapy strategies","volume":"31","author":"Wagner","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines6030054","article-title":"Early investigations and recent advances in intraperitoneal immunotherapy for peritoneal metastasis","volume":"6","author":"Thadi","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00599-8","article-title":"Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer","volume":"4","author":"Zheng","year":"2023","journal-title":"Nat Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.04.029","article-title":"Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study","volume":"32","author":"Zhang","year":"2024","journal-title":"Mol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1592995","article-title":"Recombinant human adenovirus type 5 administration for the treatment of malignant ascites or pleural effusion in cancer patients: A meta-analysis","volume":"15","author":"Duan","year":"2025","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1500570","article-title":"Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment","volume":"15","author":"Jennings","year":"2024","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1778721","article-title":"Intranodal administration of neoantigen peptide-loaded dendritic cell vaccine elicits epitope-specific T cell responses and clinical effects in a patient with chemorefractory ovarian cancer with malignant ascites","volume":"50","author":"Morisaki","year":"2021","journal-title":"Immunol Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.74834","article-title":"Peritoneal dissemination and malignant ascites in duodenal cancer successfully treated with adoptive cell therapy using WT1- and MUC1-pulsed dendritic cells and activated T cells with no adverse effects: A case report","volume":"16","author":"Yagawa","year":"2024","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02930-y","article-title":"Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer","volume":"31","author":"Wang","year":"2026","journal-title":"Int J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102206","article-title":"Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: A single-arm, single-center, phase ib trial","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241264169","article-title":"Phase I\/II clinical study of PRaG regimen combined with intraperitoneal infusion of PD-1 inhibitor for advanced refractory solid tumors with cancerous ascites (PRaG4.0P study)","volume":"23","author":"Xu","year":"2024","journal-title":"Technol Cancer Res Treat"},{"key":"B22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12964-025-02146-7","article-title":"Combination therapy with chicoric acid and PD-1\/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model","volume":"23","author":"Lan","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12951-025-03154-y","article-title":"Injectable celastrol-loading emulsion hydrogel for immunotherapy of low-immunogenic cancer","volume":"23","author":"Liu","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814189","article-title":"Anti-tumor immunogenicity of the oncolytic virus CF33-hNIS-antiPDL1 against ex vivo peritoneal cells from gastric cancer patients","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300517","article-title":"Ferroptosis-enhanced immunotherapy with an injectable dextran-chitosan hydrogel for the treatment of malignant ascites in hepatocellular carcinoma","volume":"10","author":"Meng","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.03.001","article-title":"Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy","volume":"36","author":"Seimetz","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603881","article-title":"Characterisation of the new EpCAM-specific antibody HO-3: Implications for trifunctional antibody immunotherapy of cancer","volume":"97","author":"Ruf","year":"2007","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02187-9","article-title":"Catumaxomab: First approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4161\/hv.26065","article-title":"The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting","volume":"9","author":"Atanackovic","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26258","article-title":"Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II\/III study in patients with malignant ascites","volume":"130","author":"Ott","year":"2012","journal-title":"Int J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40164-025-00727-3","article-title":"Development and clinical trial of M701, an anti-EpCAM \u00d7 anti-CD3 bispecific antibody: A targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors","volume":"14","author":"Liu","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02514","article-title":"A bispecific antibody to link a TRAIL-based anti-tumor approach to immunotherapy","volume":"10","author":"Satta","year":"2019","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1007210","article-title":"Rapid response in relapsed follicular lymphoma with massive chylous ascites to anti-CD19 CAR T therapy using Piggy Bac: A case report","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012292","article-title":"Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396)","volume":"13","author":"Restle","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6635","article-title":"Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients","volume":"14","author":"Zhang","year":"2017","journal-title":"Oncol Lett"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2018.04.006","article-title":"Activation and propagation of tumor-infiltrating lymphocytes from malignant pleural effusion and ascites with engineered cells for costimulatory enhancement","volume":"331","author":"Xu","year":"2018","journal-title":"Cell Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12732","article-title":"Possible application of ascites-infiltrating gamma-delta T cells for adoptive immunotherapy","volume":"38","author":"Abe","year":"2018","journal-title":"Anticancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231967","article-title":"Myeloid activation clears ascites and reveals IL-27-dependent regression of metastatic ovarian cancer","volume":"221","author":"Murphy","year":"2024","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101307","article-title":"Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer","volume":"16","author":"Ozawa","year":"2022","journal-title":"Transl Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001095","article-title":"Ovarian cancer ascites inhibits transcriptional activation of NK cells partly through CA125","volume":"208","author":"Fraser","year":"2022","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140315","article-title":"Macrophage-mediated vascular permeability via VLA4\/VCAM1 pathway dictates ascites development in ovarian cancer","volume":"131","author":"Zhang","year":"2021","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01212-7","article-title":"Chemo-drugs in cell microparticles reset anti-tumor activity of macrophages by activating lysosomal P450 and nuclear hnRNPA2B1","volume":"8","author":"Wei","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-03004-z","article-title":"Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening","volume":"145","author":"Li","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-05017-1","article-title":"Single-cell profiling of gastric cancer ascites reveals an epithelial-immune dual phenotype signature predictive for anti-PD-1 immunotherapy responses","author":"Xu","year":"2026","journal-title":"BMC Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00245-24","article-title":"Ascitic microbiota alteration is associated with portal vein tumor thrombosis occurrence and prognosis in hepatocellular carcinoma","volume":"15","author":"Guo","year":"2024","journal-title":"mBio"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520986664","article-title":"Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites","volume":"49","author":"Kou","year":"2021","journal-title":"J Int Med Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.62347\/ZSWV1767","article-title":"Cabozantinib inhibits tumor growth in mice with ovarian cancer","volume":"14","author":"Stiff","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2163784","article-title":"Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease","volume":"12","author":"Shrestha","year":"2023","journal-title":"Oncoimmunology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9080932","article-title":"The anticancer efficacy of plasma-oxidized saline (POS) in the ehrlich ascites carcinoma model in vitro and in vivo","volume":"9","author":"Brito","year":"2021","journal-title":"Biomedicines"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102075","article-title":"Targeting SNCA in the treatment of malignant ascites in gastrointestinal cancer","volume":"48","author":"Kudo-Saito","year":"2024","journal-title":"Transl Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.21037\/atm-22-4267","article-title":"Molecular mechanism of CD163+ tumor-associated macrophage (TAM)-derived exosome-induced cisplatin resistance in ovarian cancer ascites","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann Transl Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1698793","article-title":"Decoding ascitic immunological niches with multi-modal machine learning reveals prognostic and chemoresistant determinants in ovarian cancer","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"41305","DOI":"10.1038\/s41598-025-25087-0","article-title":"A novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing","volume":"15","author":"Liu","year":"2025","journal-title":"Sci Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0076-7","article-title":"Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: Results of the randomised phase IIIb CASIMAS study","volume":"31","author":"Sehouli","year":"2014","journal-title":"Med Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1893803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:27:29Z","timestamp":1790940449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1893803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":56,"alternative-id":["10.3389\/fonc.2026.1893803"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1893803","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1893803"}}